50 research outputs found

    Pancreatic cancer-induced neutrophil extracellular traps: A potential contributor to cancer-associated thrombosis

    Get PDF
    Pancreatic cancer (PaCa) is a highly metastatic cancer, and patients are at high risk of developing venous thromboembolism (VTE). Neutrophil extracellular traps (NETs) have been associated with cancer metastasis and cancer-associated thrombosis, but the ability of cancer to stimulate NET release is not known. The release of NETs has been shown to be a slow process and requires reactive oxygen species (ROS) production. Studies suggest that activated platelets are important mediators in the release. Here, we show that PaCa cells can stimulate the rapid release of NETs, independently of ROS production. We further assessed the role of platelets in PaCa-induced NETs and observed a trend of increased the NET release by PaCa-primed platelets. Additionally, NETs promoted thrombus formation under venous shear stress ex vivo. Taken together, our results suggest that PaCa-induced NETs can contribute to the high risk of venous thromboembolism development in PaCa patients, and reveal NETs as a potential therapeutic target

    Information Technology Adoption by Small Businesses Owners

    Get PDF
    Small business owners need effective strategies to increase profitability. One such strategy is the adoption of information technology (IT). The purpose of this multiple case study was to explore the strategies used by small business enterprise (SBE) owners to implement IT solutions for increased profitability within 3 years of opening their business. The population consisted of 3 small business owners in Orange County Southern California who were profitable by their third year of business. The conceptual framework for this study was based upon general systems theory. Data for this study were collected through semistructured interviews and a review of company documents. Transcript review and member checking were included for validity and reliability purposes. Methodological triangulation, achieved through analysis of business plans, financial documents, and probability trends documents allowed identification of 4 emergent themes: Essential strategies small business owners use to implement IT solutions for increased profitability, the essential relationship between network orientation and successful IT implementation, the relationship between IT consultants and successful implementation, and the relationship between internal IT resources and successful implementation. The findings from this study could impact social change because when SBEs are profitable, SBE owners will contribute to the affluence of their workers, communities, local economies, and society

    Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT Pathway in pancreatic cancer cells

    Get PDF
    Background: Extensive research has reported that extracellular ADP in the tumour microenvironment can stimulate platelets through interaction with the platelet receptor P2Y12. In turn, activated platelets release biological factors supporting cancer progression. Experimental data suggest that the tumour microenvironment components, of which platelets are integral, can promote chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). Thus, overcoming chemoresistance requires combining multiple inhibitors that simultaneously target intrinsic pathways in cancer cells and extrinsic factors related to the tumour microenvironment. We aimed to determine whether ticagrelor, an inhibitor of the ADP–P2Y12 axis and a well-known antiplatelet drug, could be a therapeutic option for PDAC. Methods: We investigated a functional P2Y12 receptor and its downstream signalling in a panel of PDAC cell lines and non-cancer pancreatic cells termed hTERT-HPNE. We tested the synergistic effect of ticagrelor, a P2Y12 inhibitor, in combination with chemotherapeutic drugs (gemcitabine, paclitaxel and cisplatin), in vitro and in vivo. Results: Knockdown studies revealed that P2Y12 contributed to epidermal growth factor receptor (EGFR) activation and the expression of SLUG and ZEB1, which are transcriptional factors implicated in metastasis and chemoresistance. Studies using genetic and pharmacological inhibitors showed that the P2Y12–EGFR crosstalk enhanced cancer cell proliferation. Inhibition of P2Y12 signalling significantly reduced EGF-dependent AKT activation and promoted the anticancer activity of anti-EGFR treatment. Importantly, ticagrelor significantly decreased the proliferative capacity of cancer but not normal pancreatic cells. In vitro, synergism was observed when ticagrelor was combined with several chemodrugs. In vivo, a combination of ticagrelor with gemcitabine significantly reduced tumour growth, whereas gemcitabine or ticagrelor alone had a minimal effect. Conclusions: These findings uncover a novel effect and mechanism of action of the antiplatelet drug ticagrelor in PDAC cells and suggest a multi-functional role for ADP-P2Y12 signalling in the tumour microenvironment

    Platelet-cancer Crosstalk: Mechanisms and Therapeutic Implications

    Get PDF
    Platelets are small anucleate blood cells that are central to primary haemostasis. However, platelets are also implicated in cancer pathogenesis. This thesis showed that cancer cells promote thrombosis by activating platelets, and in turn, platelets provide cancer cells with growth factors to render cancer more aggressive and chemoresistant. The thesis demonstrated a therapeutic benefit of combined antiplatelet, ticagrelor, and chemo drugs, on cancer treatment

    Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer

    Get PDF
    Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance
    corecore